{"ModuleTitle": "Company Description", "CompanyName": "MediciNova, Inc.", "Symbol": "MNOV", "Address": "4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA, California, 92037, United States of America", "Phone": "858-373-1500", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on developing novel, small molecule\r\ntherapeutics for the treatment of serious diseases with unmet medical needs and\r\na commercial focus on the United States market. Our current strategy is to focus\r\nour development activities on MN-166 (ibudilast) for neurological disorders such\r\nas progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS),\r\nchemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy,\r\nglioblastoma, and substance dependence and addiction (e.g., methamphetamine\r\ndependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast)\r\nfor fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic\r\npulmonary fibrosis (IPF). Our pipeline also includes MN-221 (bedoradrine) for\r\nthe treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid\r\ntumor cancers.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f13%2f0001564590-20-004605.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Edward C. Stepanow", "title": "Chief Financial Officer"}, {"name": "Kazuko Matsuda", "title": "Director & Chief Medical Officer"}, {"name": "Yuichi Iwaki", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}